Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

20121,472 citationsJournal Articlegreen Open Access

Authors

This trial was registered at ClinicalTrial.gov with the number NCT01009281.

Good health and well-being

Published in: Gut

Volume 61, Issue 12, pp. 1693-1700

Field-Weighted Citation Impact: 56.23